Body mass index and resistance to recombinant human erythropoietin therapy in maintenance hemodialysis patients

Renal Failure

Volumn 35, Issue 10, 2013, Pages 1392-1398

  Do Sameiro Faria, Maria ^a,b   Ribeiro, Sandra ^a,c   Rocha Pereira, Petronila ^c,d   Fernandes, João ^c,e   Reis, Flávio ^e   Bronze Da Rocha, Elsa ^a,c   Miranda, Vasco ^b   Quintanilha, Alexandre ^a,c   Costa, Elísio ^a,c   Belo, Luís ^a,c   Santos Silva, Alice ^a,c  

^a UNIVERSITY OF PORTO   (Portugal)

^b FRESENIUS MEDICAL CARE PORTUGAL   (Portugal)

^c UNIVERSITY OF PORTO   (Portugal)

^d UNIVERSITY OF BEIRA INTERIOR   (Portugal)

^e UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Anemia; BMI; Body mass index; EPO; Erythropoietin; Hemodialysis; Inflammation; Resistance to rhEPO

Indexed keywords

ADIPONECTIN; ALBUMIN; C REACTIVE PROTEIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; INTERLEUKIN 6; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SOLUBLE TRANSFERRIN RECEPTOR; TRANSFERRIN; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; ARTIFICIAL KIDNEY; BODY MASS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HORMONE BLOOD LEVEL; HUMAN; INFLAMMATION; IRON BLOOD LEVEL; IRON METABOLISM; IRON THERAPY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; RETICULOCYTE COUNT; TRANSFERRIN BLOOD LEVEL; TREATMENT RESPONSE; UNDERWEIGHT;

AGED; AGED, 80 AND OVER; ANEMIA; BODY MASS INDEX; CASE-CONTROL STUDIES; DRUG RESISTANCE; ERYTHROPOIETIN; FEMALE; HUMANS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RENAL DIALYSIS;

EID: 84885895511     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.828267     Document Type: Article

References (35)

1. Locatelli F, Conte F, Marcelli D. The impact of hematocrit levels and erythropoietin treatment on overall and cardiovascular mortality and morbidity-The experience of the Lombardy dialysis registry. Nephrol Dial Transplant. 1998;13:1642-1644
2. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in hemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121-132
3. Bárány P. Inflammation, serum C-reactive protein, and erythropoietin resistance. Nephrol Dial Transplant. 2001;16:224-227
4. Smrzova J, Balla J, Bárány P. Inflammation and resistance to erythropoiesis-stimulating agents-what do we know and what needs to be clarified? Nephrol Dial Transplant. 2005; 20(Suppl 8):viii2-viii7
5. Macdougall IC, Cooper AC. Erythropoietin resistance: The role of inflammation and pro-inflammatory cytokines. Nephrol Dial Transplant. 2002;17(Suppl 11):39-43
6. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy morbidity and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28: 53-61
7. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase response predicts erythropoietin resistance in hemodialysis and peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63-72
8. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis. 2001;38:1408-1413
9. Pupim LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int. 2004;65: 2371-2379
10. Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: Which is the chicken and which is the egg? Semin Dial. 2004;17:449-454
11. Cuevas X, García F, Martín-Malo A, et al. Risk factors associated with cardiovascular morbidity and mortality in Spanish incident hemodialysis patients: Two-year results from the ANSWER Study. Blood Purif. 2011;33:21-29
12. Yen TH, Lin JL, Lin-Tan DT, Hsu CW. Association between body mass and mortality in maintenance hemodialysis patients. Ther Apher Dial. 2010;14:400-408
13. Tanner RM, Brown TM, Muntner P. Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease. Curr Hypertens Rep. 2012;14:152-159
14. Kalantar-Zadeh K, Abbott KC, Salahudeen AK, Kilpatrick RD, Horwich TB. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81:543-554
15. Kalaitzidis RG, Siamopoulos KC. The role of obesity in kidney disease: Recent findings and potential mechanisms. Int Urol Nephrol. 2011;43:771-784
16. Hillman RS, Ault KA. Clinical approach to anemia. In: Hillman RS, Ault KA. eds. Hematology in Clinical Practice. 3rd edn. New York: McGraw-Hill; 2002:12-26
17. Strippoli GF, Manno C, Schena FP, Craig JC. Hemoglobin and hematocrit targets for the anaemia of chronic renal disease (Cochrane review). Cochrane Database Syst Rev. 2003;1: CD003967
18. Costa E, Lima M, Alves JM, et al. Inflammation, T-cell phenotype, and inflammatory cytokines in chronic kidney disease patients under hemodialysis and its relationship to resistance to recombinant human erythropoietin therapy. J Clin Immunol. 2008;28:268-275
19. Costa E, Pereira BJ, Rocha-Pereira P, et al. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients. Am J Nephrol. 2008;28:677-683
20. Bazeley J, Bieber B, Li Y, et al. C-reactive protein and prediction of 1-year mortality in prevalent hemodialysis patients. Clin J Am Soc Nephrol. 2011;6:2452-2456
21. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A. Oxidative stress and inflammation: Implications in uremia and hemodialysis. Clin Biochem. 2011;44:1189-1198
22. Jacober ML, Mamoni RL, Lima CS, Dos Anjos BL, Grotto HZ. Anaemia in patients with cancer: Role of inflammatory activity on iron metabolism and severity of anaemia. Med Oncol. 2007;24: 323-329
23. Fleming RE, Sly WS. Hepcidin: A putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA. 2001;98:8160-8162
24. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression trough STAT3. Blood. 2006;108:3204-3209
25. Dallalio G, Fleury T, Means RT. Serum hepcidin in clinical specimens. Br J Hematol. 2003;122:996-1000
26. Kulaksiz H, Gehrke SG, Janetzko A, et al. Pro-hepcidin: Expression and cell specific localisation in the liver and its regulation in hereditary hemochromatosis, chronic renal insufficiency, and renal anemia. Gut. 2004;53:735-743
27. Hsu SP, Ching CK, Chien CT, Hung KY. Plasma prohepcidin positively correlates with hematocrit in chronic hemodialysis patients. Blood Purif. 2006;24:311-316
28. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911-920
29. Fantuzzi G. Adiponectin and inflammation: Consensus and controversy. J Allergy Clin Immunol. 2008;121:326-330
30. Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55:667-674
31. Nascimento H, Silva L, Lourenço P, et al. Lipid profile in Portuguese obese children and adolescents: Interaction of apolipoprotein E polymorphism with adiponectin levels. Arch Pediatr Adolesc Med. 2009;163:1030-1036
32. Nascimento H, Costa E, Rocha-Pereira P, et al. Cardiovascular risk factors in portuguese obese children and adolescents: Impact of small reductions in body mass index imposed by lifestyle modifications. Open Biochem J. 2012;6:43-50
33. Adamczak M, Chudek J, Wiecek A. Adiponectin in patients with chronic kidney disease. Semin Dial. 2009;22:391-395
34. Eleftheriadis T, Liakopoulos V, Antoniadi G, Kartsios C, Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 2009;22:70-77
35. Tussing-Humphreys LM, Nemeth E, Fantuzzi G, et al. Elevated systemic hepcidin and iron depletion in obese premenopausal females. Obesity. 2010;18:1449-1456